Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.55 INR | +1.55% | +9.17% | +2.34% |
Valuation
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 188.5 | 116.2 | 46.78 | 304.2 | 673.4 | 346.1 |
Enterprise Value (EV) 1 | 140 | 116.6 | 95.79 | 368 | 725.1 | 391.5 |
P/E ratio | 48.8 x | 29.7 x | 18.5 x | 82.2 x | 64.2 x | 21 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.44 x | 0.29 x | 0.12 x | 0.6 x | 0.91 x | 0.46 x |
EV / Revenue | 0.33 x | 0.29 x | 0.24 x | 0.72 x | 0.98 x | 0.53 x |
EV / EBITDA | 13 x | 15.2 x | 8.57 x | 24.1 x | 24.4 x | 13.1 x |
EV / FCF | -23.6 x | -2.34 x | -1.59 x | -13.8 x | 60.3 x | -6.52 x |
FCF Yield | -4.23% | -42.7% | -62.8% | -7.27% | 1.66% | -15.3% |
Price to Book | 1.72 x | 1 x | 0.4 x | 1.94 x | 4.11 x | 0.83 x |
Nbr of stocks (in thousands) | 32,528 | 32,528 | 34,195 | 50,028 | 50,028 | 87,614 |
Reference price 2 | 5.796 | 3.573 | 1.368 | 6.080 | 13.46 | 3.950 |
Announcement Date | 9/1/18 | 8/31/19 | 8/21/20 | 8/16/21 | 8/27/22 | 8/7/23 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 423.7 | 397.2 | 400.3 | 510.4 | 740.4 | 744.9 |
EBITDA 1 | 10.79 | 7.698 | 11.18 | 15.26 | 29.71 | 29.79 |
EBIT 1 | 7.643 | 4.724 | 7.67 | 10.89 | 20.01 | 19.74 |
Operating Margin | 1.8% | 1.19% | 1.92% | 2.13% | 2.7% | 2.65% |
Earnings before Tax (EBT) 1 | 4.879 | 4.749 | 4.807 | 5.042 | 14.61 | 15.77 |
Net income 1 | 3.861 | 4.11 | 3.468 | 3.731 | 10.49 | 11.25 |
Net margin | 0.91% | 1.03% | 0.87% | 0.73% | 1.42% | 1.51% |
EPS 2 | 0.1187 | 0.1202 | 0.0738 | 0.0740 | 0.2096 | 0.1881 |
Free Cash Flow 1 | -5.921 | -49.83 | -60.19 | -26.75 | 12.04 | -60.09 |
FCF margin | -1.4% | -12.55% | -15.04% | -5.24% | 1.63% | -8.07% |
FCF Conversion (EBITDA) | - | - | - | - | 40.51% | - |
FCF Conversion (Net income) | - | - | - | - | 114.75% | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 9/1/18 | 8/31/19 | 8/21/20 | 8/16/21 | 8/27/22 | 8/7/23 |
Balance Sheet Analysis
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 0.41 | 49 | 63.8 | 51.8 | 45.4 |
Net Cash position 1 | 48.5 | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | 0.0533 x | 4.383 x | 4.18 x | 1.742 x | 1.525 x |
Free Cash Flow 1 | -5.92 | -49.8 | -60.2 | -26.7 | 12 | -60.1 |
ROE (net income / shareholders' equity) | 6.48% | 3.56% | 2.47% | 2.37% | 6.55% | 3.87% |
ROA (Net income/ Total Assets) | 2.97% | 1.57% | 2.32% | 2.66% | 4.38% | 2.81% |
Assets 1 | 130 | 261.5 | 149.5 | 140 | 239.2 | 399.9 |
Book Value Per Share 2 | 3.360 | 3.560 | 3.400 | 3.130 | 3.270 | 4.760 |
Cash Flow per Share 2 | 1.630 | 0.2100 | 0.0300 | 0.0500 | 0.0100 | 0.0400 |
Capex | - | - | 14 | 35.3 | 21.2 | 4.56 |
Capex / Sales | - | - | 3.5% | 6.91% | 2.87% | 0.61% |
Announcement Date | 9/1/18 | 8/31/19 | 8/21/20 | 8/16/21 | 8/27/22 | 8/7/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+2.34% | 6.88M | |
+11.33% | 11.43B | |
-0.75% | 5.77B | |
-4.08% | 4.87B | |
-23.66% | 2.58B | |
-5.06% | 1.75B | |
-24.53% | 1.11B | |
-23.66% | 882M | |
-18.46% | 865M | |
+24.67% | 855M |
- Stock Market
- Equities
- AJOONI Stock
- Financials Ajooni Biotech Limited